Prokarium Promotes Livija Deban to Chief Scientific Officer to Drive Pipeline Expansion in Cancer Immunotherapy
2.11.2021 12:00:00 EET | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Livija Deban, PhD, as Chief Scientific Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102005305/en/
Livija Deban, Chief Scientific Officer of Prokarium (Photo: Business Wire)
“Since joining Prokarium, Livija has been central to the strategic and operational development of the company’s immuno-oncology portfolio, including our next-generation Salmonella platform,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “I look forward to closely working with her and the team to establish Prokarium as a recognized leader in microbial immunotherapy.”
“At Prokarium, we are leveraging cutting edge science at the intersection of immunology and synthetic biology to develop innovative therapies for the treatment of solid tumors,” said Dr. Deban. “Our approach builds on the long history of microbial immunotherapy and holds the promise of providing solutions to many clinical needs that cannot be addressed by current cancer therapeutics. I am honored to be appointed as CSO and am excited to work with the leadership team and the board to accelerate our pipeline.”
Dr. Deban previously served as Prokarium’s Vice President of Research. Prior to joining Prokarium, she led the immuno-oncology R&D at Oxford BioTherapeutics, where she focused on the target discovery and the development of antibodies for cancer treatment. Previously, Dr. Deban conducted her postdoctoral academic research at Cancer Research UK and King’s College London. She received her master’s degree in Medical Biotechnology from the University of Bologna and holds a PhD in Basic and Applied Immunology from University Vita-Salute San Raffaele, Italy.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK. For further information, visit https://www.prokarium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005305/en/
Contact information
For Prokarium
Kristen Albright
Chief Executive Officer
kristen.albright@prokarium.com
www.prokarium.com
For media
MacDougall
Matthew Corcoran or Mario Brkulj
+1 781-235-3060 or +49 175 5711 562
prokarium@macbiocom.com
www.macbiocom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul
Klarna Submits Application for U.S. Banking License6.7.2026 15:30:00 EEST | Press release
Klarna (NYSE: KLAR), the global digital bank and flexible payments provider, today announced it has submitted applications to the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation (FDIC) to establish Klarna Bank USA, a proposed Utah-chartered industrial bank. Klarna has operated as a licensed bank in Europe since 2017 and serves U.S. customers through valued partner banks. Since 2019, Klarna has provided Americans with access to over $91.3 billion in responsible credit, saving them more than $5.1 billion in interest compared to revolving credit card debt. Today, 30 million Americans use Klarna each year, and hundreds of thousands of merchants rely on Klarna to grow their businesses. "Banking is built on trust," said Sebastian Siemiatkowski, co-founder and CEO of Klarna. "We've seen firsthand the appetite for a fairer, more transparent approach in the U.S., and our own banking license is the natural next step, giving customers tools to borrow respon
IQM Quantum Computers Acquires Assets of Quantistry GmbH to Bridge the Gap Between Quantum Algorithms and Solutions for Industrial Enterprises6.7.2026 15:00:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, has acquired selected assets of Quantistry GmbH, a Berlin-based developer of cloud-native simulation workflow platform for automotive, aerospace, chemical, materials and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706448170/en/ IQM Quantum Computers Acquires Assets of Quantistry GmbH to bridge the gap between Quantum Algorithms and Solutions for Industrial Enterprises The acquired assets include proprietary software applications, algorithms, and intellectual property. IQM will also retain Quantistry's core technical, quantum chemistry, and software engineering talent, ensuring seamless continuity and rapid platform integration. The transaction completed recently, concurrently with IQM's business combination with Real Asset Acquisition Corp. (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom